Identification of protein kinase C beta as a therapeutic target for neuroendocrine prostate cancer and development of a nanoparticle-based therapeutic strategy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification of protein kinase C beta as a therapeutic target for neuroendocrine prostate cancer and development of a nanoparticle-based therapeutic strategy
Authors
Keywords
-
Journal
Nano Today
Volume 48, Issue -, Pages 101705
Publisher
Elsevier BV
Online
2022-11-25
DOI
10.1016/j.nantod.2022.101705
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages
- (2022) Xiangang Huang et al. Nature Protocols
- A DNA origami-based aptamer nanoarray for potent and reversible anticoagulation in hemodialysis
- (2021) Shuai Zhao et al. Nature Communications
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Activated ALK Cooperates with N-Myc via Wnt/β-catenin Signaling to Induce Neuroendocrine Prostate Cancer
- (2021) Kenji Unno et al. CANCER RESEARCH
- Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
- (2021) Anthony R Mato et al. LANCET
- Multifunctional biomolecule nanostructures for cancer therapy
- (2021) Jing Wang et al. Nature Reviews Materials
- Targeting Protein Kinase C in Glioblastoma Treatment
- (2021) Noelia Geribaldi-Doldán et al. Biomedicines
- Structural and Binding Effects of Chemical Modifications on Thrombin Binding Aptamer (TBA)
- (2021) Vibhav Valsangkar et al. MOLECULES
- Molecular events in neuroendocrine prostate cancer development
- (2021) Yong Wang et al. Nature Reviews Urology
- Epigenetic modulations and lineage plasticity in advanced prostate cancer
- (2020) R. Ge et al. ANNALS OF ONCOLOGY
- Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
- (2020) Aaron T. Scott et al. CLINICAL CANCER RESEARCH
- TACC3 promotes prostate cancer cell proliferation and restrains primary cilium formation
- (2020) Yunkai Qie et al. EXPERIMENTAL CELL RESEARCH
- Small molecules, big impact: 20 years of targeted therapy in oncology
- (2020) Philippe L Bedard et al. LANCET
- A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy
- (2020) Nagesh Kishan Panchal et al. LIFE SCIENCES
- Evolution of a highly functional circular DNA aptamer in serum
- (2020) Yu Mao et al. NUCLEIC ACIDS RESEARCH
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- (2020) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- The progress and perspective of strategies to improve tumor penetration of nanomedicines
- (2020) Jiang Hu et al. CHINESE CHEMICAL LETTERS
- Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma
- (2019) Yizi He et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Kinase PIM1 promotes prostate cancer cell growth via c-Myc-RPS7-driven ribosomal stress
- (2019) Changwen Zhang et al. CARCINOGENESIS
- Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer
- (2019) Miguel Reina-Campos et al. CANCER CELL
- Octreotide Conjugates for Tumor Targeting and Imaging
- (2019) Eduard Figueras et al. Pharmaceutics
- Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies
- (2019) Nikolas G. Balanis et al. CANCER CELL
- LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling
- (2019) Jie Luo et al. Nature Communications
- SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate cancer
- (2019) Haiying Li et al. LABORATORY INVESTIGATION
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Protein kinase C alpha-mediated phosphorylation of PIM-1L promotes the survival and proliferation of acute myeloid leukemia cells
- (2018) Mayu Takami et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Combined therapy of imatinib and an anti-CTLA4 immune-checkpoint inhibitor
- (2018) Kinam Park JOURNAL OF CONTROLLED RELEASE
- SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition
- (2017) Yinan Li et al. EUROPEAN UROLOGY
- Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
- (2017) Sheng Yu Ku et al. SCIENCE
- N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
- (2016) Etienne Dardenne et al. CANCER CELL
- Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS)
- (2015) F. Posch et al. CLINICAL CANCER RESEARCH
- The potential of enzastaurin to enhance platelet aggregation and growth factor secretion: implications for cancer cell survival
- (2015) G. Lesyk et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- PKC- as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL
- (2014) D. El-Gamal et al. BLOOD
- The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials
- (2014) L. L. Zhang et al. Clinical & Translational Oncology
- Genomewide RNAi screen identifies protein kinase Cβ and new members of mitogen-activated protein kinase pathway as regulators of melanoma cell growth and metastasis
- (2014) Madeleine Schönherr et al. Pigment Cell & Melanoma Research
- Protein kinase C (PKC) isozyme-specific substrates and their design
- (2012) Jeong-Hun Kang et al. BIOTECHNOLOGY ADVANCES
- Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers
- (2012) Jhanelle E. Gray et al. CANCER
- Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog
- (2012) Nazneen Dubey et al. DRUG DELIVERY
- Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics
- (2012) Nwabundo Nwankwo et al. INVESTIGATIONAL NEW DRUGS
- A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer
- (2011) Robert A. Wolff et al. CANCER
- Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors
- (2011) D. Mole et al. ENDOCRINE-RELATED CANCER
- Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules
- (2010) A Körner et al. BRITISH JOURNAL OF CANCER
- Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma
- (2010) J Wang et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More